News
First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia Press Release May 22, 2017 SyneuRx International (Taiwan) Corp. today announced that the…
First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial Press Release May 11, 2017 SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized…
FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment Press Release Apr 04, 2016 Germantown, MD, USA (April 4, 2016) - SyneuRx announced today,…
SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults Press Release Dec 19, 2015 Taipei, December 19, 2015- SyneuRx International (Taiwan) Corp.,…
